PD-L1 expression

P2, N=316, Active, not recruiting, GlaxoSmithKline | Trial completion date: Jul 2027 --> Dec 2027 | Trial primary completion date: Jul 2027 --> Sep 2026

Taken together, these findings offer novel insights into the role and mechanism of NAT10 in the crosstalk between cisplatin chemoresistance and immunosuppression in gastric cancer. NAT10 thus holds promise as a highly attractive target, with the potential to synergize with PD-1-based immunotherapy to reverse cisplatin resistance in gastric cancer.

Collectively, our findings demonstrate that HY-oAd can enhance intratumoral accumulation of 177Lu-aPD-L1 in a multifaceted manner to elicit synergistic antitumor immune response against desmoplastic and poorly immunogenic pancreatic tumors.

The patient exhibited vascular endothelial growth factor receptor amplification, mutations in CHEK1, ERCC3, and TP53, deletion of CD274 (gene of PD-L1), and microsatellite stability. These findings suggest that immunotherapy may be beneficial to URCS patients with low PD-L1 expression and microsatellite stability, when accompanied by immunotherapy-associated genetic alterations.

P1, N=12, Completed, The Methodist Hospital Research Institute | Active, not recruiting --> Completed

Image-based PD-L1 scoring on TC% combined with LTR ≥ 1 serves as a predictive biomarker for both pathological response and EFS in NSCLC patients receiving neoadjuvant chemoimmunotherapy. LTR can serve as a surrogate for TILs scoring and predicts long-term EFS.

This study highlights the heterogeneous molecular landscape of UM and underscores the importance of integrating histopathological and molecular data for improved prognostic stratification. The identification of potential therapeutic targets and atypical mutations typically associated with other melanoma subtypes suggests avenues for future research and tailored therapeutic strategies.

Indeed, thanks to a visual-estimation-based assessment of PD-L1 expression, TAP has improved reproducibility and reduced scoring time, but large-scale validation is ongoing and certain interpretive challenges remain. Finally, we propose a standardized reporting template to enhance consistency in diagnostic practice, together with our perspective on future improvements and challenges of PD-L1 assessment.

Circ-PVT1 is upregulated in CRC patients and encoded a novel protein: PVT1-104aa. PVT1-104aa promotes CRC progression and predicts worse prognosis. PVT1-104aa enhance Myc expression through inhibition of Myc ubiquitination. PVT1-104aa regulate PD-L1 expression of CRC cells and modulate T cells infiltration in vivo.

Collectively, these findings indicate that CEP55 promotes liver cancer immune escape and malignant progression through modulation of STAT1-dependent PD-L1/MHC-I expression, oxidative stress, and immunosuppressive signaling. Targeting CEP55 may therefore represent a potential strategy to improve antitumor immune recognition in liver cancer.

The GPC3 × PD-L1 bsAb retained high affinity for GPC3 while exhibiting a ~ 300-fold reduced affinity for membrane PD-L1 compared to atezolizumab, enabling GPC3-dependent PD-1/PD-L1 blockade...Biodistribution studies further confirmed preferential accumulation of the GPC3 × PD-L1 bsAb in GPC3-positive tumors. Collectively, these data provide proof-of-concept (POC) validation for the efficacy and safety of a tumor-targeted immune checkpoint inhibitor, highlighting its potential to enhance tumor specificity and reduce systemic toxicity for GPC3-expressing malignancies such as hepatocellular carcinoma.

Lung adenocarcinomas are characterized by a high prevalence of targetable alterations, with KRAS G12C representing the most frequent alteration. KRAS mutation status showed limited prognostic relevance. These findings support routine molecular testing and integration of genomic and clinical data to guide personalized treatment.